WorldHeart IPO proceeds to fund development of fully implantable ventricular assist device.
This article was originally published in The Gray Sheet
Executive SummaryWORLDHEART'S $11.5 MIL. PROCEEDS FROM INITIAL PUBLIC OFFERING are earmarked to help support early-stage development of its HeartSaver fully implantable ventricular assist device. Intended for treatment of end-stage heart failure as an alternative to heart transplant, the "remotely powered and monitored" HeartSaver is the first VAD "totally implantable in the chest cavity," according to a prospectus for the Ottawa, Ontario-based firm's IPO, which was completed on Dec. 17.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.